Original Article

Association of angiotensin-converting enzyme G2350A gene polymorphisms with hypertension among patients with intracerebral haemorrhage

Imran Imran, PhD\textsuperscript{a}, Syahrul Syahrul, PhD\textsuperscript{b}, Sofia Sofia, PhD\textsuperscript{c}, Farida Farida, PhD\textsuperscript{a}, Nasrul Musadir, PhD\textsuperscript{a} and Jonny K. Fajar, MD\textsuperscript{d},\textsuperscript{*}

\textsuperscript{a} Department of Neurology, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia
\textsuperscript{b} Department of Neurology, Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia
\textsuperscript{c} Department of Biochemistry, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia
\textsuperscript{d} Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia

Received 6 January 2019; revised 21 April 2019; accepted 24 April 2019; Available online 25 May 2019

Abstract

Objectives: To evaluate the correlation of angiotensin-converting enzyme (ACE) G2350A gene polymorphisms with hypertension, brain hematoma volume (BHV), level of consciousness, and disease outcome among intracerebral haemorrhage (ICH) patients.

Methods: A cross-sectional study was conducted in Zainoel Abidin General Hospital from May 2016 to June 2017. Polymerase chain reaction was used to genotype ACE G2350A gene polymorphisms. BHV was assessed using the ABC/2 volume estimation formula. Level of consciousness was assessed by Glasgow coma scale (GCS). Disease outcome was assessed using Glasgow outcome scale (GOS). Association tests for ACE G2350A genotype in the context of hypertension status, BHV, GCS score, and GOS score in subjects with ICH was analysed by multiple logistic regression.

Results: A total of 75 ICH patients were included in the study. Of those, 59 patients exhibited hypertension, 24 patients had BHV $\geq$ 60 cm$^3$, 16 patients possessed GCS

* Corresponding author: Medical Research Unit, School of Medicine, Universitas Syiah Kuala, Jl. T Tanoeh Abe, Darussalam, Banda Aceh 23111, Indonesia.
E-mail: gembyok@gmail.com (J.K. Fajar)

Peer review under responsibility of Taibah University.

© 2019 The Authors. Production and hosting by Elsevier Ltd on behalf of Taibah University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). https://doi.org/10.1016/j.jtumed.2019.04.004
Intracerebral haemorrhage (ICH), the second most common sub-type of stroke, is a devastating critical disease associated with the highest morbidity and mortality of all stroke sub-types.1,2 Serious morbidity and mortality of ICH had been reported, where it was revealed that more than one third of patients with ICH did not survive, and functional independence was regained by only approximately 20% of the patients.3 The morbidity rate of ICH varies, ranging from 22.9 to 51.8 per 100 000 population,2 and the mortality rate (the 30-day mortality rate) ranges from 35% to 52% of all ICH patients.4 The high mortality rate observed for ICH is triggered by several factors including hypertension,5 brain hematoma volume (BHV),6 level of consciousness, and disease outcome. Of these factors, it has been suggested that hypertension plays a central role in affecting the other factors. In the pathophysiology of ICH, higher blood pressure is directly proportional to larger BHV,6 and this pathological state has a crucial impact on decreased consciousness and poor prognosis in ICH patients.9 Additionally, a recent study found that hypertension was considered the main predictor for in-hospital mortality among ICH patients.5

In the pathogenesis of hypertension, it has been disclosed that angiotensin-converting enzyme (ACE) plays an important role in the renin-angiotensin-aldosterone system (RAAS) to cause vasoconstriction. In the RAAS, angiotensinogen is cleaved by renin into angiotensin I, and angiotensin I is subsequently cleaved into angiotensin II by ACE. Angiotensin II mainly affects the RAAS, where it induces vasoconstriction, sodium retention, and proliferative effects. These mechanisms are the forerunners for the development of hypertension.10,11 Therefore, it has been hypothesized that ACE may possess a potential correlation with these aggravating factors that include hypertension, BHV, level of consciousness, and disease outcome among ICH patients. The ACE G2350A gene is one of ACE genes that play a significant role in determining the ACE level within the circulation.12 Therefore, our study aimed to evaluate the association of ACE G2350A gene polymorphisms with hypertension, BHV, level of consciousness, and disease outcome among patients with ICH.

Materials and Methods

Study designs and patients

From May 2016 to June 2017, a cross-sectional study was conducted in Zainoel Abidin General Hospital, Banda Aceh, Indonesia to evaluate the correlation of ACE G2350A gene polymorphism with hypertension, level of consciousness, disease outcome, and BHV among patients with ICH. All enrolled ICH patients were treated in our Hospital, and all patients were Acehnese, which is one of the ethnic groups in Indonesia. To confirm the diagnosis of ICH, brain computed tomography (CT) scans (Dual Source CT Scanner, Siemens Healthcare, Erlangen, Germany) was performed on all patients with clinical conditions and neurological examination related to ICH.13 Blood pressure (supine), performed at least three times, was measured after the patients had rested for at least 15 min using both a blood pressure monitor and an auscultatory method.14 The hypertension diagnosis was assessed using standard criteria formulated by the Joint National Committee VII.15 BHV was measured using the ABC/2 volume estimation as described by previous studies.16,17 Additionally, Glasgow coma scale (GCS) score was used to evaluate level of consciousness,18 and disease outcome was determined using Glasgow outcome scale (GOS) score.19 Patients experiencing severe infection, abnormal blood electrolyte levels, patients with ICH related to trauma, neoplasms, coagulation disorders or thrombolytic therapy, aneurysms, or other vascular malformations were excluded.

Genotyping of ACE G2350A gene polymorphism

Blood samples were collected in 10 ml Sodium - Ethylenediaminetetraacetic acid (Na2-EDTA) tubes and kept frozen at –20 °C. DNA was extracted using standard protocols adapted from previous studies11,20–22 A set of primers (forward 5'-CTGACGAAATGGATGGCCGC-3' and reverse 5'-TTGATGAGTTCCACGTATT TCG-3') was designed to cover the polymorphic region of the ACE G2350A gene. A thermal cycler (Perkin Elmer 2400, Boston, USA) was used to amplify the DNA. A 10 mL total reaction volume contained 100–200 ng DNA templates, 125 mM dNTPs, 2.5 mM MgCl2, 0.3 mM primers, and 1U Taq polymerase. DNA was amplified for 35 cycles, and each cycle consisted of pre-denaturation at 95 °C for 5 min, denaturation at 94 °C for 30 s, annealing at 58 °C for 30 s, extension at 72 °C for 30 s, and post-extension at 72 °C for 10 min. DNA sequencing was performed using BioEdit software (BioEdit, Carlsbad, USA). A fast digest BstU1 (Thermo Fisher Scientific, Waltham, USA) was used to digest the PCR products. We used 2% agarose gel (Hoeffer, Holliston, USA) to separate the digested fragments, and digested fragments were identified using ethidium bromide staining under ultraviolet transillumination. A 122-bp fragment was visualized as allele G2350, 100-bp and 22-
bp fragments were visualised as allele A2350, and 122–100 and 22 bp were visualised as the GA genotype.

Statistical analysis

The association of ACE G2350A gene polymorphism with hypertension, level of consciousness, disease outcome, and BHV among patients with ICH was analysed using multiple logistic regression. All significance tests were two tailed, and P-values of <0.05 were considered statistically significant. Statistical Package of Social Sciences 17.0 software (SPSS Inc., Chicago, IL) was used to analyse the data.

Results

During the study period, a total of 75 ICH patients were recruited for the study. Of those, hypertension was observed in 59 patients. The mean age for the normotension group was 54.50 years, and for hypertension group the mean age was 55.88 years. Approximately 56.25% and 52.54% patients were male for the normotension and the hypertension group, respectively. Other baseline characteristics of the patients included in our study are described in Table 1. Our analysis found that the baseline characteristics between the normotension and the hypertension groups were not significantly different (P > 0.05), and therefore, our data were considered homogeneous.

Table 2 shows the distributions of the genotypes frequencies of ACE G2350A gene polymorphisms in the normotension and the hypertension groups. The genotype frequencies were 81.25% for GG, 18.75% for GA, 0% for AA in patients with normotension, and they were 49.15% for GG, 47.46% for GA, and 3.39% for AA in subjects exhibiting hypertension. For the allele frequencies, approximately 90.63% for G and 9.38% for A were observed in the normotension group, and 72.88% and 27.12% for the G and the A allele, respectively, were observed in hypertension group. Our analysis found that the A allele was associated with a 3.60-fold increased risk for hypertension among ICH patients.

The distributions of genotype frequencies of ACE G2350A gene polymorphisms for GCS ≤8 and GCS ≥9 are described in Table 3. The genotype frequencies were 56.25%, 43.75%, and 0.00% for GG, GA, and AA respectively in patients exhibiting a GCS ≤8. For patients with a GCS ≥9, the frequencies for GG, GA, and AA were 55.93%, 40.68%, and 3.39%, respectively. Our analysis found no
association between level of consciousness and ACE G2350A gene polymorphisms among ICH patients.

We summarize the genotype frequencies of ACE G2350A gene polymorphisms in patients with GOS of 1–3 and GOS of 4–5 in Table 4. The genotype frequencies for patients with GOS of 1–3 were 55.56% for GG, 41.67% for GA, and 2.78% for AA. For patients with GOS of 4–5, the frequencies were 66.67%, 33.33%, and 0.00% for GG, GA, and AA, respectively. Our findings indicated no association between GOS and ACE G2350A gene polymorphisms among ICH patients.

Table 5 summarizes the genotype frequencies of ACE G2350A gene polymorphisms in patients with BHV of 0–60 and BHV >60. We observed 58.82% for GG, 37.25% for GA, and 3.92% for AA in patients with BHV of 0–60. For BHV >60, the frequencies for GG, GA, and AA were 50.00%, 50.00%, and 0.00%, respectively. Our analysis found no association between BHV and ACE G2350A gene polymorphisms among ICH patients.

**Discussion**

It is widely established that ICH patients have widely varying prognoses, and these are influenced by several factors including hypertension, level of consciousness, disease outcome, and BHV. In addition to the factors, genetic polymorphisms may also play a crucial role in determining ICH prognosis. Our study reported the correlation of ACE G2350A gene polymorphisms with the risk of hypertension, level of consciousness, disease outcome, and BHV among patients with ICH.

Our results indicated that the A allele of ACE G2350A gene polymorphisms was associated with an increased risk for hypertension among patients with ICH. It has been reported that hypertension plays a crucial role in the development of ICH, and the pathogenesis of hypertension is closely influenced by ACE. Hypertension is a pathological state characterized by narrowing of the arteriolar lumen. This abnormality is closely related to vasoconstriction and vascular hypertrophy. This narrowing of the arteriolar lumen may occur due to complex mechanisms involving the autonomic nervous system and both circulating and local vasoconstrictors including ACE. It has been reported that ACE plays an important role in influencing the levels of the potent vasoconstrictor angiotensin. In hypertension, angiotensin II, through various mechanisms, leads to direct vasoconstriction of precapillary arterioles and post-capillary venules and stimulates hypertrophy of vascular smooth muscle cells. This mechanism may explain the correlation between hypertension and ACE G2350A gene polymorphisms among ICH patients as reported in our results.

Until now, no study reports the influence of ACE G2350A gene polymorphisms in hypertensive subjects with ICH. Therefore, we could not compare our results systematically with the results of previous studies. Previous studies have only reported the correlation between ACE G2350A gene polymorphisms and hypertension among ICH patients. We observed 58.82% for GG, 37.25% for GA, and 3.92% for AA in patients with BHV of 0–60. For BHV >60, the frequencies for GG, GA, and AA were 50.00%, 50.00%, and 0.00%, respectively. Our analysis found no association between BHV and ACE G2350A gene polymorphisms among ICH patients.

**Table 4:** The association between genotypes and alleles frequencies of ACE G2350 gene polymorphisms and glasgow outcome scale among ICH patients.

| Genotypes and alleles | GOS 1–3 (n = 72) | GOS 4–5 (n = 3) | OR (95%CI) | p |
|-----------------------|-----------------|----------------|------------|---|
| GG vs. GA+AA          | 40 (55.56)      | 2 (66.67)      | 0.63       | 0.706 |
| GA vs. GG             | 30 (41.67)      | 1 (33.33)      | 1.43       | 0.775 |
| GG+AA vs. AA          | 2 (2.78)        | 0 (0.00)       | 0.25       | 0.396 |

**Table 5:** The association between genotypes and alleles frequencies of ACE G2350A gene polymorphisms and brain hematoma volume among ICH patients.

| Genotypes and alleles | BHV<60 cm³ (n = 51) | BHV≥61 cm³ (n = 24) | OR (95%CI) | p |
|-----------------------|---------------------|---------------------|------------|---|
| GG vs. GA+AA          | 30 (58.82)          | 12 (50.00)          | 0.70       | 0.474 |
| GA vs. GG             | 19 (37.25)          | 12 (50.00)          | 1.68       | 0.298 |
| GG+AA vs. AA          | 2 (3.92)            | 0 (0.00)            | 0.40       | 0.564 |
| G vs. A               | 79 (77.45)          | 36 (75.00)          | 0.87 (0.39–1.95) | 0.741 |
| A vs. G               | 23 (22.55)          | 12 (25.00)          | 1.15 (0.51–2.55) | 0.741 |

Notes: Data were presented as n (%); ACE, angiotensin-converting enzyme; ICH, intracerebral hemorrhage; GOS, glasgow outcome scale; OR, odds ratio; CI, confidence interval.

**Figure 1:** Forest plot of the association between ACE G.
polymorphisms and hypertension. Of those, four studies found that ACE G2350A gene polymorphisms were associated with the risk of hypertension, and in contrast, four other studies indicated no association. We attempted to combine the data from those previous studies with our data, and our pooled calculation found that ACE G2350A gene polymorphisms were not associated with the risk of hypertension (Figure 1). The results of our pooled calculation were contrary to those of a previous meta-analysis. This previous study found that the A allele was associated with a protective effect against the risk of hypertension; however, data discrepancies between the report and the references were observed in the meta-analysis. Therefore, the accuracy of the meta-analysis is still in doubt. In the near future, we expect that there will be a meta-analysis report involving a larger and more accurate data set.

The prognosis of ICH patients is influenced by several aggravating factors including BHV, level of consciousness, and disease outcome. Although it is difficult to describe the exact mechanism regarding the association between ACE and these aggravating factors, there is an assumption that a linear correlation may exist between ACE and these aggravating factors. Elevated BHV scores usually lead to a decreased level of consciousness as a result of increased intracranial pressure, and this condition is associated with a poor prognosis and low GOS score. Indeed, BHV was considered more important than GCS in determining the treatment option in patients with ICH. Additionally, a large BHV was demonstrated to be associated with elevated blood pressure, and hypertension was shown to correlate with ACE G2350A gene polymorphisms. This suggested that ACE G2350A gene polymorphisms should have an impact on BHV and other aggravating factors; however, our study failed to show a correlation between these aggravating factors and ACE G2350A gene polymorphisms. These results are puzzling, and the absence of a clear correlation theory may be the main reason for these results. Additionally, the currently existing assumption was based solely on the low rational possibilities. In addition, no study reports the correlation between ACE and these aggravating factors among patients with ICH. This may explain the existence of no correlation between ACE G2350A gene polymorphisms and several aggravating factors including BHV, level of consciousness, and disease outcome as reported in our results.

There were several limitations in our current study. First, several precipitating factors including smoking status, alcohol consumption, and the use of sympathomimetic drugs were not included in the study. Second, false positive findings may occur due to small sample size. Third, our samples were only recruited from a single centre, and therefore the bias probability could not be ruled out.

Conclusions

In our population, the A allele of ACE G2350A gene polymorphisms is associated with increased risk for hypertension among ICH patients, and ACE G2350A gene polymorphisms exhibit no significant correlation with BHV, level of consciousness, and disease outcome. Our results provide the first evidence concerning ACE G2350A gene polymorphisms in hypertensive subjects with ICH.

Source of funding

There is no external funding for our study.

Conflict of interest

The authors have no conflict of interest to declare.

Ethical approval

The study was approved by the Institutional Review Board of Universitas Syiah Kuala, Banda Aceh, Indonesia (No. 039/KE/FK/2016) in accordance with the Declaration of Helsinki. All subjects and/or their family provided written informed consent prior to participation in this study.

Authors’ contributions

Idea/concept: II; Design: II; SS. Control/supervision: II; SS; SS. Data collection/processing: II; SS; SS; FF; NM; JKF. Extraction/Analysis/interpretation: II; SS; SS; FF; NM; JKF. Literature review: II; JKF. Writing the article: II; JKF. Critical review: II; SS; JKF. All authors have critically reviewed and approved the final draft and are responsible for the content and similarity index of the manuscript.

References

1. Carpenter AM, Singh IP, Gandhi CD, Prestigiacomo CJ. Genetic risk factors for spontaneous intracerebral haemorrhage. Nat Rev Neurol 2016; 12(1): 40–49.
2. An SJ, Kim TJ, Yoon BW. Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: an update. J Stroke 2017; 19(1): 3–10.
3. Sahni R, Weinberger J. Management of intracerebral hemorrhage. Vase Health Risk Manag 2007; 3(5): 701–709.
4. Cuceres JA, Goldstein JN. Intracranial hemorrhage. Emerg Med Clin N Am 2012; 30(3): 771–794.
5. Hevesi M, Bershad EM, Jafari M, Mayer SA, Selim M, Suarez JI, Divani AA. Untreated hypertension as predictor of in-hospital mortality in intracerebral hemorrhage: a multicenter study. J Crit Care 2018; 43: 235–239.
6. Panchal HN, Shah MS, Shah DS. Intracerebral hemorrhage score and volume as an independent predictor of mortality in primary intracerebral hemorrhage patients. Indian J Surg 2015; 77(Suppl 2): 302–304.
7. Nilsson OG, Lindgren A, Brandt L, Säveland H. Prediction of death in patients with primary intracerebral hemorrhage: a prospective study of a defined population. J Neurosurg 2002; 97(3): 531–536.
8. Rodriguez-Luna D, Rodriguez-Villatoro N, Juega JM, Boned S, Muchada M, Sanjuan E, Pagola J, Rubiera M, Ribo M, Coscojuela P, Molina CA. Prehospital systolic blood pressure is related to intracerebral hemorrhage volume on admission. Stroke 2018; 49(1): 204–206.
9. Aguilar MI, Brett TG. Update in intracerebral hemorrhage. Neurohospitalist 2011; 1(3): 148–159.
10. Moniwa N, Varagie J, Simington SW, Ahmad S, Nagata S, Voncannon JL, Ferrario CM. Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism. Am J Physiol Heart Circ Physiol 2013; 305(5): H644–H650.
11. Rohman MS, Fajar JK, Kuncayho BH, Yunita L, Sidarta EP, Saka PNB, Heriansyah T, Widodo N. Angiotensin-converting
enzyme (ACE) I/D and bradykinin B2 receptor T/C genes polymorphism in patients with ACE inhibitors-related cough. *Egypt J Med Hum Genet* 2018; 19(4): 307–313.

12. Niu W, Qi Y, Gao P, Zhu D. Association between angiotensin converting enzyme G2350A polymorphism and hypertension risk: a meta-analysis. *J Renin-Angiotensin-Aldosterone Syst JRAAS* 2011; 12(1): 8–14.

13. Gong QW, Liao MF, Liu L, Xiong XY, Zhang Q, Zhong Q, Zhou K, Yang YR, Meng ZY, Gong CX, Xu R, Yang QW. CD36 gene polymorphisms are associated with intracerebral hemorrhage susceptibility in a Han Chinese population. *BioMed Res Int* 2017; 2017: 5352071.

14. Rose GA, Blackburn H. Cardiovascular survey methods. WHO (World Health Organ) Monogr Ser 1968; 56: 90–95.

15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. Joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. National heart, lung, and blood institute; national high blood pressure education program coordinating committee. Seventh report of the Joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. *Hypertension* 2003; 42(6): 1206–1252.

16. Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J. The ABCs of measuring intracerebral hemorrhage volumes. *Stroke* 1996; 27(8): 1304–1305.

17. Kleinman JT, Hillis AE, Jordan LC. ABC/2: estimating intracerebral hemorrhage volume and total brain volume, and predicting outcome in children. *Dev Med Child Neuroi* 2011; 53(3): 281–284.

18. Nik A, Sheikh Andalibi MS, Ehsaei MR, Zarifian A, Ghayoor Karimiani E, Bahadorokhan G. The efficacy of Glasgow coma scale (GCS) score and acute physiology and chronic health evaluation (APACHE) II for predicting hospital mortality of ICU patients with acute traumatic brain injury. *Bull Emerg Trauma* 2018; 6(2): 141–145.

19. Woischneck D, Firsching R. Efficiency of the Glasgow Outcome Scale (GOS)-Score for the long-term follow-up after severe brain injuries. *Acta Neurochir Suppl* 1998; 71: 138–141.

20. Saeed-Mahmood M, Saboohi K, Osman Ali S, Bokhari AM, Frossard PM. Association of the angiotensin-converting enzyme (ACE) gene G2350A dimorphism with essential hypertension. *J Hum Hypertens* 2003; 17(10): 719–723.

21. Yang XJ. Angiotensin-converting enzyme gene 2350 G/A polymorphism is associated with left ventricular hypertrophy but not essential hypertension. *Hypertens Res* 2007; 30(1): 31–37.

22. Niu W, Qi Y, Hou S, Zhai X, Zhou W, Qiu C. Haplotype-based association of the renin-angiotensin-aldosterone system genes polymorphisms with essential hypertension among Han Chinese: the Fangshang study. *J Hypertens* 2009; 27(7): 1384–1391.

23. Nawaz SK, Hasnain S. Effect of ACE polymorphisms on the association between noise and hypertension in a Pakistani population. *J Renin-Angiotensin-Aldosterone Syst JRAAS* 2011; 12(4): 516–520.

24. Dhanachandra-Singh Kh, Jajodia A, Kaur H, Kukreti R, Kartihkeyan M. Gender specific association of RAS gene polymorphism with essential hypertension: a case-control study. *BioMed Res Int* 2014; 2014: 538053.

25. Wilson D, Charidimou A, Shakeshaft C, Ambler G, White M, Cohen H, Yousry T, Al-Shahi Salman R, Lip GY, Brown MM, Jäger HR, Werring DJ. CROMIS-2 collaborators. Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. *Neurology* 2016; 86(4): 360–366.

26. Minimi S, Devan WJ, Radmanesh F, Miyares L, Poterba T, Hansen BM, Norrving B, Jimenez-Conde J, Gilart-Alanizhauer E, Eloua R, Cuadrado-Godía E, Soriano C, Roquer J, Kourkoulis CE, Ayres AM, Schwab K, Tirschwell DL, Selim M, Brown DL, Silliman SL, Worrall BB, Meschia JF, Kidwell CS, Montaner J, Fernandez-Cadenas I, Delgado P, Greenberg SM, Lindgren A, Matouk C, Sheth KN, Woo D, Anderson CD, Rosand J, Falcone GJ. International stroke genetics consortium. 17p12 influences hematoma volume and outcome in spontaneous intracerebral hemorrhage. *Stroke* 2018; 49(7): 1618–1625.

27. Cho DY, Chen CC, Lee HC, Lee WY, Lin HL. Glasgow Coma Scale and hematoma volume as criteria for treatment of putaminal and thalamic intracerebral hemorrhage. *Surg Neurol* 2008; 70(6): 628–633.

28. Hatcher S, Chen C, Govindarajan P. Prehospital systolic hypertension and outcomes in patients with spontaneous intracerebral hemorrhage. *Cureus* 2017; 9(1): e98.

---

**How to cite this article:** Imran I, Syahrul S, Sofia S, Farida F, Musadir N, Fajar JK. Association of angiotensin-converting enzyme G2350A gene polymorphisms with hypertension among patients with intracerebral haemorrhage. *J Taibah Univ Med Sc* 2019;14(3):300–305.